John Nosenzo - 11 Feb 2022 Form 4 Insider Report for Bioventus Inc. (BVS)

Role
Chief Commercial Officer
Signature
/s/ Anthony D'Adamio, Attorney-in-Fact
Issuer symbol
BVS
Transactions as of
11 Feb 2022
Transactions value $
-$6,401
Form type
4
Filing time
15 Feb 2022, 20:17:44 UTC
Previous filing
14 Feb 2022
Next filing
21 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BVS Class A Common Stock Options Exercise +1.47K +3.46% 43.9K 11 Feb 2022 Direct F1
transaction BVS Class A Common Stock Sale -$6.4K -534 -1.22% $11.99 43.4K 14 Feb 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BVS Restricted Stock Units Options Exercise $0 -1.47K -100% $0.00* 0 11 Feb 2022 Class A Common Stock 1.47K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Class A common stock.
F2 Reflects shares sold to cover taxes upon the vesting of restricted stock units on February 11, 2022 pursuant to a standing 10b5-1 instruction.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.87 to $11.99, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 The restricted stock units vested on February 11, 2022.